Literature DB >> 22513453

Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-κB.

M Sisto1, S Lisi, D D Lofrumento, M D'Amore, M A Frassanito, D Ribatti.   

Abstract

We explore the involvement of tumor necrosis factor α (TNF-α)-converting enzyme (TACE) in vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2) (VEGF-A/VEGFR2)-mediated angiogenesis in Sjögren's syndrome (SS), one of the most common autoimmune rheumatic diseases. To test the hypothesis that SS autoantibodies (Abs) regulate VEGF-A/VEGFR2 expression by a TACE-dependent nuclear factor-κB (NF-κB) activation pathway, their effects on the expression and activation of the VEGF-A/TACE/VEGFR2/NF-κB pathway were determined in human salivary gland epithelial cells (SGEC). An enhanced angiogenesis in SS salivary gland biopsies was observed, associated with an increased VEGF-A expression and activation of VEGF-A/VEGFR2 signaling. Human cytokine array analysis of the pro-inflammatory and pro-angiogenic protein response in SGEC treated with SS Abs revealed an overexpression of multiple pro-angiogenic factors. TACE RNA knockdown, the use of anti-VEGF-A monoclonal antibody and the inhibition of NF-κB activity significantly abrogated the release of pro-angiogenic factors, demonstrating that VEGF-A/TACE/VEGFR2/NF-κB axis dysfunction may be contributory to pathogenesis and exacerbation of this autoimmune condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513453     DOI: 10.1038/gene.2012.9

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  17 in total

1.  Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20.

Authors:  M Sisto; A Barca; D D Lofrumento; S Lisi
Journal:  Clin Exp Immunol       Date:  2016-02-23       Impact factor: 4.330

2.  Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Massimo D'Amore; Dario D Lofrumento
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

3.  Characterization of Angiogenesis and Lymphangiogenesis in Human Minor Salivary Glands with Sjögren's Syndrome.

Authors:  Andrew D McCall; Olga J Baker
Journal:  J Histochem Cytochem       Date:  2015-01-30       Impact factor: 2.479

4.  GRO-α/CXCR2 system and ADAM17 correlated expression in Sjögren's syndrome.

Authors:  Sabrina Lisi; Margherita Sisto; Dario Domenico Lofrumento; Massimo D'Amore; Raffaella De Lucro; Domenico Ribatti
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

5.  Salivary gland expression level of IκBα regulatory protein in Sjögren's syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Dario Domenico Lofrumento; Giuseppe Ingravallo; Raffaella De Lucro; Massimo D'Amore
Journal:  J Mol Histol       Date:  2013-02-03       Impact factor: 2.611

6.  A potential role of the GRO-α/CXCR2 system in Sjögren's syndrome: regulatory effects of pro-inflammatory cytokines.

Authors:  Sabrina Lisi; Margherita Sisto; Dario Domenico Lofrumento; Massimo D'Amore; Raffaella De Lucro; Domenico Ribatti
Journal:  Histochem Cell Biol       Date:  2012-10-05       Impact factor: 4.304

7.  Neovascularization is prominent in the chronic inflammatory lesions of Sjögren's syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Giuseppe Ingravallo; Dario Domenico Lofrumento; Massimo D'Amore; Domenico Ribatti
Journal:  Int J Exp Pathol       Date:  2014-04       Impact factor: 1.925

8.  Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.

Authors:  Sabrina Lisi; Margherita Sisto; Domenico Ribatti; Massimo D'Amore; Raffella De Lucro; Maria Antonia Frassanito; Loredana Lorusso; Angelo Vacca; Dario Domenico Lofrumento
Journal:  J Mol Med (Berl)       Date:  2014-02-21       Impact factor: 4.599

9.  Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement.

Authors:  Serena Vettori; Rosaria Irace; Antonella Riccardi; Daniela Iacono; Luciana Pellecchia; Lucia Vicedomini; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-08-26       Impact factor: 2.980

Review 10.  Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.

Authors:  Thi Hong Van Le; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.